Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban Alone vs Edoxaban Plus Antiplatelet in Atrial Fibrillation With Stable Coronary Artery Disease
KCT0003387Phase 3Completed
- Sponsor
- Cardiovascular Research Foundation
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of edoxaban in Atrial fibrillation (AFib) and coronary arteriosclerosis (2 arms), sponsored by Cardiovascular Research Foundation. Started May 2019; status: completed.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)coronary arteriosclerosis
Beyond the preview
Go deeper on KCT0003387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003387.